docetaxel anhydrous has been researched along with Mesothelioma in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gkini, E; Gkiozos, I; Katirtzoglou, N; Kotteas, E; Makrilia, N; Ralli, M; Syrigos, K; Tourkantonis, I | 1 |
| Alamara, C; Charpidou, A; Kotanidou, A; Makrilia, N; Nikolaidis, I; Ralli, M; Syrigos, K; Tourkantonis, I; Tsimpoukis, S | 1 |
| Kang, WK; Kim, ST; Lee, J; Lim, HY; Park, JO; Park, JY; Park, SH; Park, YS | 1 |
| Castro, J; Ghawanmeh, T; Laytragoon-Lewin, N; Murray, F; Thunberg, U | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Loprevite, M; Pirani, P; Semino, C | 1 |
| Adak, S; Aisner, S; Belani, CP; Johnson, DH; Levitan, N; Stella, PJ | 1 |
| Jekunen, A; Knuuttila, A; Linnainmaa, K; Mattson, K; Ollikainen, T; Suhonen, S; Taavitsainen, M | 1 |
| Halme, M; Jekunen, A; Kivisaari, L; Knuuttila, A; Linnainmaa, K; Mali, P; Mattson, K; Ollikainen, T | 1 |
| Abratt, RP; Chasen, MR; Cronje, N; Fourie, L; Hacking, D; McMichael, G; Rapoport, BL; Vorobiof, DA | 1 |
5 trial(s) available for docetaxel anhydrous and Mesothelioma
| Article | Year |
|---|---|
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Taxoids; United States | 2004 |
Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Feasibility Studies; Female; Humans; Irinotecan; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pleural Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Malignant pleural mesothelioma: a phase II trial with docetaxel.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Pleural Neoplasms; Survival Rate; Taxoids | 2002 |
5 other study(ies) available for docetaxel anhydrous and Mesothelioma
| Article | Year |
|---|---|
The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Pemetrexed; Peritoneal Neoplasms; Pleural Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2010 |
miR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment.
Topics: Antineoplastic Agents; Cell Cycle; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Humans; Mesothelioma; MicroRNAs; Radiation-Sensitizing Agents; Taxoids; Tumor Suppressor Protein p53 | 2011 |
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Division; Cell Line; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Fenretinide; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topotecan | 2003 |
[Multi-target tumor therapy].
Topics: Antimetabolites, Antineoplastic; Asbestosis; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Enzyme Inhibitors; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Neoplasm Recurrence, Local; Pemetrexed; Pleural Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2005 |
In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Transformed; Cell Survival; Comet Assay; Deoxycytidine; DNA Damage; Docetaxel; Epithelial Cells; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |